Researchers identified a very rare mutation in a Libyan man who was diagnosed with late-onset familial amyloid polyneuropathy (FAP), according to a case report. The report, titled “Familial amyloid polyneuropathy due to p.ALA140 SER mutation,” appeared in the journal Neurology India. FAP is a rare,…
Vyndaqel (tafamidis) significantly delays the progression of familial amyloid polyneuropathy (FAP) and improves the quality of life of FAP patients, a real-world study shows. These results support data from clinical trials showing that Vyndaqel is an effective treatment for FAP. The study, “Positive Effectiveness of Tafamidis…
Japanese experts have developed guidelines for treating people in their country with transthyretin familial amyloid polyneuropathy that are different from other countries’ guidelines. That’s because TTR-FAP manifests itself differently in Japanese than in people elsewhere. It has a broader range of symptoms in Japanese patients, for example. The guidelines are…